PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportshemophilia a
MeSH D006467 - hemophilia a
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D025861:Inherited blood coagulation disorders
$
Success rate
D020147:Coagulation protein disorders
0 Companies
0 Drugs
Success rate
D006474:Hemorrhagic disorders
$
Success rate
D006467: 
Hemophilia a
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
BaxaltaRurioctocog alfa pegol Adynovi  2018-01-08   
BayerAntihemophilic factor human recombinant Helixate NexGen  2000-08-04   
Antihemophilic factor human recombinant Iblias  2016-02-18   
Antihemophilic factor human recombinant Kogenate Bayer  2000-08-04   
Antihemophilic factor human recombinant Kovaltry  2016-02-18   
BioMarin PharmaceuticalValoctocogene roxaparvovec Roctavian  2023-06-29 $16.338 M Q3/23-Q3/24 
CSL BehringLonoctocog alfa Afstyla  2017-01-04   
Antihemophilic factor, Von willebrand factor human Voncento  2013-08-12   
GenentechEmicizumab Hemlibra  2017-11-16   
Laboratoire Francais du Fractionnement et des Biotechnologies S.A.Coagulation factor viia recombinant human Cevenfacta  2022-07-15   
Novo NordiskTuroctocog alfa Esperoct  2019-06-20   
Turoctocog alfa NovoEight  2013-11-13   
Coagulation factor viia recombinant human NovoSeven  1996-02-23   
OctapharmaSimoctocog alfa Nuwiq  2014-07-22   
Simoctocog alfa Vihuma  2017-02-13   
Orphan MedicalEfmoroctocog alfa Elocta  2015-11-18   
PfizerMoroctocog alfa ReFacto  1999-04-13 $230 M Y2023 
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
86%
19/22
Phase 2
91%
20/22
Phase 3
83%
29/35
Approved: 14Overall Success rate: 65%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Baxalta
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use